Modified GRF 1-29 and Ipamorelin are separate peptides, which research indicates may work synergistically to induce potential growth hormone release and growth hormone pulses. This increase may result in several downstream physiological activities associated with increased growth hormone release. Modified GRF 1-29 peptide is an analog of growth hormone-releasing hormone (GHRH).^[1] It is also known as tetra-substituted GRF (1-29), and is composed of a sequence thought to be the smallest necessary to interact with GHRH receptors, specifically the first 29 amino acids of GHRH. On the other hand, Ipamorelin is suggested to act via binding to growth hormone secretagogue (GHS) receptors.^[2] These receptors are also known as the ghrelin receptors, and Ipamorelin appears to be a highly selective pentapeptide that binds and activates them.

Generally, GRF (1-29) has a short half-life that limits its research potential. However, the structurally modified version of the tetra-substituted peptide, Modified GRF 1-29, is considered to boast a longer half-life and has, therefore, been considered by researchers as a more viable compound for use during experimental research. There are significant structural differences between Modified GRF 1-29 and its unmodified counterpart, mainly due to the substitution of four specific amino acids within the sequence. These changes occur at the 2nd, 8th, 15th, and 27th positions and are believed to possibly enhance the peptide’s stability against enzymatic degradation, particularly from enzymes like dipeptidyl peptidase-4 (DPP-4). For example, the substitution of L-alanine with D-alanine at the 2nd position might improve resistance to molecular breakdown. Replacing asparagine with glutamine at the 8th position might potentially reduce the risk of asparagine rearrangement and amide hydrolysis. The replacement of glycine with alanine at the 15th position is thought to possibly increase bioactivity. Lastly, the change from methionine to leucine at the 27th position is believed to help prevent methionine oxidation.

Likewise, Ipamorelin appears to have a high sensitivity to growth hormone secretagogue receptors, potentially leading to superior viability under research conditions. Combination of these peptides may lead to an increase in growth hormone response compared to control levels.